PHARMACOVIGILANCE STUDY OF ANTIASTHMATIC AGENTS IN PATIENTS OF BRONCHIAL ASTHMA AT A TERTIARY CARE CENTRE.

  • Professor Pharmacology, Dr. VMGMC Solapur (MAH).
  • Postgraduate students, Dr. VMGMC Solapur (MAH).
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

ABSTRACT Background: Bronchial asthma is one of the most common chronic disease in the world affecting around 334 million people. Management of bronchial asthma includes multidrug therapy for long duration, which leads its association with adverse drug reactions (ADRs). Pharmacovigilance studies of antiasthmatic agents are scare in India.Therefore, the present study was planned to monitor and evaluate adverse drug reactions associated with antiasthmatic agents. Objectives: The present study was conducted to study the pattern, causality and severity analysis of adverse drug reactions associated with antiasthmatic agents in a tertiary care centre. Materials and Methods: 150 patients of either gender, ageing above 18 years with established bronchial asthma attending outpatient and inpatient department of medicine at a tertiary care centre interviewed during the time period of October 2016 to February 2017.Central Drugs Standard Control Organisation (CDSCO) ADR forms were filled. World Health Organisation-Upasala Monitoring Centre (WHO-UMC) causality categories were used for assessment of causality. Severity of ADRs was assessed by using Hartwig and seigels scale. Results: A total 33 ADRs were reported in 23 patients out of 150 bronchial asthma patients. Among the 23 patients reported with ADRs 10 (43.47%) were male while 13 (56.52%) were female. Oral thrush was most common ADR (33.33%) followed by palpitation (15.15%), sore throat (12.12 %), running nose, tremors (each 9.09%), dry mouth, GI distress, bitter taste (each 6.06%) and headache (3.03%) among the patients of bronchial asthma receiving antiasthmatic agents. Most ADRs were associated with inhalational Beclomathasone (58.33%) followed by inhalational budesonide (25%), montelukast (23.07%), salbutamol (18.75%), theophylline (14.29%), ipatropium (7.4%) and salmeterol (02.22%). According to WHO-UMC categories 48.57% ADRs were found to be probable while 51.42% were possible. Highest percentage of ADRs 75.79% were classified as mild and 24.24% were moderate on Hartwig and Seigle scale. Conclusion: Results of our study highlighted the need for ADR monitoring of antiasthamatics in asthma patient. Patients receiving inhalational steroids needs to be proper councelling and also written advice about cleansing mouth after steroid inhalation to reduce the risk of oral thrush. Key words: Pharmacovigilance, antiasthmatic agents, WHO-UMC causality categories, Hartwig and Seigel scale

  1. Peter JB. 2008. Asthma. In: Braunwald E, Frauci S, Kasper DL, Hauser SL, Lango DL, Jameson JL, editors. Harrison?s principles of internal medicine. 18th ed. New York: McGraw-Hill.1596-1606.
  2. Masoli M, Fabian D, Holt S, Beasley R. 2004. Global Initiative for Asthma (GINA) programme. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 59: 469-78.
  3. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. 2012. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 12: 204.
  4. The Global Asthma Report 2014. Auckland, New Zealand:Global Asthma Network, 2014. Available from: http://www.globalasthmareport.org/resources/Global_ Asthma_Report_ 2014. pdf, [last accessed on March 13, 2017.]
  5. Aggarwal AN, Chaudhry K, Chhabra SK, D?Souza GA, Gupta D, Jindal SK, et al. 2006. Prevalence and risk factors for bronchial asthma in Indian adults: a multicentre study. Indian J Chest Dis Allied Sci. 48: 13-22.
  6. Agarwal R, Denning DW, Chakrabarti A. 2014. Estimation of the burden of chronic and allergic pulmonary aspergillosis in India. PLoS One. 9: e114745.
  7. Murthy KJR, Sastry JG. 2005. Economic burden of asthma. In: Background Papers-Burden of disease in India. New Delhi: Ministry of Health and Family Welfare, National Commission on Macroeconomics and Health. 251?63.
  8. Requirements for adverse drug reaction reporting. Geneva: 1975. WHO. 1039-109.
  9. WHO policy perspective of medicines, Pharmacovigilance: 2004. Ensuring the safe use of medicines. Geneva: WHO. 1222-39.
  10. Garg KC, Singhal KC, Kumar S.1993. Monitoring the adverse profile of atenolol a collaborative study.?Indian J PhysiolPharmacol.?37:213?6.
  11. Kallergis EM, Manios EG, Kanoupakis EM, Schiza SE, Mavrakis HE, Klapsinos NK, et al. 2005. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest. 127:2057-63
  12. Bajaj A, Balakrishna S, Sawarkar S. 1999. Assessment of therapeutic performances of inhalation aerosols and clinical pharmacist's services in PFT lab. Indian J Hosp Pharm. 36:138-42.
  13. Uppsala Monitoring Centre(2006), the use of the World Health Organization ? Uppsala Monitoring Centre(WHO-UMC) system for standardized case causality assessment.
  14. NICE CKS, July 2013 (UK access only). Candida- oral.
  15. Worthington HV, Clarkson JE, Khalid J, et al, Interventions for treating oral candidiasis for patients with cancer receiving treatment. Conchrane database Syst ???? 2010 July 7? (7): CD001972. doi: 10.1002/1465/858. CD001972.pub 4.
  16. Garcia-Cuesta C,,Sarrion-Perez MG, Bagan JV; Current treatment of oral candidiasis: A literature review. J clin Exp Dent. 2014 DEC 1 6(5) :e578-82 doi ?????????? 4317/jced.51798. eCollection 2014 Dec.
  17. Centers for Disease control and prevention.(2014). Oropharyngeal/Esopharyngeal Candidiasis (?Thrush?).
  18. Godara N, Godara R, Khullar M, Impact of inhalational therapy on oral health. Lung . 2011 Oct-Dec; 28(4): 272-75.

[U. P. Gawali and Anuradha deshkar. (2017); PHARMACOVIGILANCE STUDY OF ANTIASTHMATIC AGENTS IN PATIENTS OF BRONCHIAL ASTHMA AT A TERTIARY CARE CENTRE. Int. J. of Adv. Res. 5 (Mar). 1867-1871] (ISSN 2320-5407). www.journalijar.com

Ujwala P. Gawali
Dr. VMGMC Solapur (MAH)

DOI:

Article DOI: 10.21474/IJAR01/3703      
DOI URL: https://dx.doi.org/10.21474/IJAR01/3703

Download Full Paper

Download PDF No. of Downloads: 87 | No. of Views: 319